Top Tweets for #Transmedics
$TMDX
המניה ממשיכה במומנטום חיובי בתוך הGAP לאחר פריצת קו המגמה היורד, וככל שתתבסס מעל 80 דולר הדרך עשויה להיפתח לעבר סגירת הGAP באזור 95 דולר.
#TMDX #TransMedics #Trading

Organ transplant innovator $TMDX reports Q2 earnings on Aug 4. Massive growth expected from aviation logistics fleet expansion, but market watches rising competition from XVIVO's lower-cost alternatives. 🫀 #TransMedics #MedTech #Stocks
$TMDX -22% postmarket.
No gustaron los resultados de #transmedics, con reducción casi a la mitad de su BPA.

Join us at the #TransMedics Evening Symposium at the #ILTSCongress2026.
OCS Liver Experience with 11,000 Liver Transplants – A New Standard of Care for Liver Transplantation Globally
Date: May 7th | 18:15-19:30 | Room K
More details at: https://t.co/3aoOjcf7ih

$TMDX TransMedics
ドナー臓器を体外で"生きたまま"保存・輸送するOrgan Care Systemで移植医療を変革。
FY2025は売上37%増の$605M、純利益$190Mと過去最高益を達成。
OCS肝移植は全米の36%を占め、自社航空機22機で臓器を空輸する唯一無二の存在。
#TransMedics #TMDX #米国株 #ヘルスケア #移植医療 #投資

Impresionante subida de $TMDX hoy! 🚀
Las acciones de TransMedics se disparan más de un 9% alcanzando los $144.80.
El mercado sigue premiando su liderazgo en tecnología de preservación de órganos y su sólida logística.
¡A un paso de máximos históricos!
🏥💎 #TransMedics #StockMarket #TMDX #BioTech

Witness $TMDX's impressive 165% upswing. Health technology is cooking, with volumes hitting 1,083,243. Worth watching! #stockstowatch #TransMedics
Heating Up: TransMedics Group
Symbol: $TMDX
Price: 127.67
Volume: 1,083,243
% Up: 165%

$TMDX 突破了 #TransMedics
我之前一直有记得CEO 在116左右买了超多自家股票… 所以在它下跌后买了目标仓位的2/3,今天确认突破后买齐最后1/3 …
理由如下:(重点是“该机构移植追踪数据显示”)
这是实打实的数据,不是空口无凭的唱多…
具体内容:
“TransMedics 被 Needham 升级为“买入”评级(原为“持有”)
Needham 将 TransMedics 评级从“持有”上调至“买入”,并给予 148美元 的目标价。该机构移植追踪数据显示,TransMedics 第三季度美国销售额有望超过市场共识,分析师在研报中向投资者表示。
该行还预计,公司的新心脏和肺部临床试验以及国际化扩张将在2026年成为增长驱动力。与此同时,TransMedics 的利润率“正在快速提升”,这将推动盈利预期上调,分析师认为。
Needham 认为,该公司在一个仍严重渗透不足的市场中拥有显著领先优势。”

$TMDX
Notición de #transmedics
TransMedics $TMDX, oficializa su expansión a Europa, comenzando por Italia, mediante una alianza con Mercedes-Benz.
La empresa quiere traer su exitosa tecnología al viejo continente, desplegando una una red logística terrestre adaptada exclusivamente al transporte de órganos.
Se prevé que las operaciones comiencen antes de finales de 2025.
Muy interesante como sigue ejecutando esta empresa, la cual venimos siguiendo desde principios de año.
Si queréis saber un poco más de ella, echadle un ojo al post mencionado:
$TMDX
TransMedics İçin Yükseliş Senaryoları Güçleniyor
Organ nakli teknolojisini yeniden şekillendiren #TransMedics, Organ Bakım Sistemi (OCS) ile dikkatleri üzerine çekiyor. Şirket, geleneksel soğuk depolama yöntemlerine kıyasla organların canlılığını daha uzun süre koruyarak nakil başarı oranlarını artırma potansiyeli taşıyor.
Boğa piyasası beklentilerini destekleyen birkaç önemli gelişme var:
🔹 **FDA Onayları:** Yeni nesil OCS kalp ve akciğer denemeleri için alınan FDA onayları, şirketin pazar potansiyelini genişletme yolunda önemli adımlar olarak görülüyor.
🔹 **Güçlü Büyüme:** Şirket, son bir yılda %48'lik gelir artışı elde etti ve 2025 yılı için gelir beklentisini 585 milyon - 605 milyon dolar aralığına yükseltti. Analistler, önümüzdeki üç yıl boyunca yıllık %20'nin üzerinde gelir artışı öngörüyor.
🔹 **Yönetici Güveni:** CEO'nun yaklaşık 2 milyon dolarlık hisse alımı yapması, şirket yönetimin geleceğe olan inancını gösteren bir işaret olarak yorumlanıyor.
Analistler de hisse için iyimser. TD Cowen 170 dolar, Piper Sandler ise 145 dolar hedef fiyat belirlemiş durumda. Hisse, 15 Eylül itibarıyla 114.29 dolardan işlem görüyordu. Bu gelişmeler, şirketin organ nakli alanındaki devrimci yaklaşımının finansal sonuçlara yansımaya başladığını düşündürüyor.
#SP500 #Nasdaq #Dowjones #Borsa #Hisse
$TMDX
Mínimos ascendentes para #transmedics, que a lo mejor son el inicio de buscar los máximos históricos.


$TMDX Updated Flight data.

Will $TMDX be the SMASH of 2025?
#shorts #marketmastery #tmdx #transmedics #biotech #investsmarter #stocksavvyshay #bigquench #supportlevel #timetobuy #smashorpass #tradingtips #stockmarket
📈 Weekly US #StockMarket Recap Dec.2-6:
#SP500 up +0.83%!
🚀Top Gainers:
$SOUN #SoundHound AI +63%
https://t.co/cCuNOzjAJR
$ASAN #Asana +45%
$KC #Kingsoft Cloud +23%
📉Top Losers:
$BHIL #Benson Hill -33%
$TMDX #TransMedics -22%
$NKLA #Nikola -20%
#Investing #Stocks #Trading

TransMedics Q3: Is the -31% Drop A Buying Opportunity? (TMDX Stock Analysis) $TMDX #TransMedics https://t.co/HKYfPGTGVK
#TransMedics
#トランスメディックス決算
REDFORD REPORTS-298
Q3決算を受け、売り推奨
TransMedics Group (NASDAQ: TMDX) は、第3四半期の予想EPSが0.12ドル(予想は0.29ドル)、売上高が1億880万ドルと予想を下回った。ただし、同社は黒字転換を果たし、売上高は前年比で64%増加した。
利益率のトレードオフ:サービス収益(利益率が低い)の割合が高まったため、売上総利益は前年同期の61%から56%に減少した。
成長の見通し:同社は2024年の売上高見通しを4億2500万ドルから4億4500万ドルと強気の見方を維持しており、前年比で最大84%の成長を示唆している。
この決算を受け、株価は時間外で22%を超える大幅安となっている。先週まで株価は、ステージ3にあったが、本日の急落を受けステージ4入りすると思われる。チャート的には完全に売り推奨となった。
ただし売り上げの急増、黒字化の達成など、ポジティブな側面を持つため、今後もWatch Listに載せておき
業績の追跡調査を行って頂きたいです。
REDFORD

💥 $TMDX plunges 24%+ after hours.
Q3 Revenue: $108.8M (+64% YoY), missed $115M target
EPS: $0.12 vs. expected $0.26
Full-Year Guidance: strong at $425-445M.
Is this an overreaction, or a signal for caution? 🤔
#TransMedics #StockMarket
$TMDX | Post Market: -25% | TransMedics Q3 Earnings Report: Revenue up 64% YoY to $108.8M, EPS at $0.12! Gross Margin at 56% 📈 #Earnings #TransMedics
👉 Business Highlights:
➡️ 𝐓𝐨𝐭𝐚𝐥 𝐫𝐞𝐯𝐞𝐧𝐮𝐞 reached $108.8M, a 64% YoY increase from $66.4M.
➡️ 𝐍𝐞𝐭 𝐢𝐧𝐜𝐨𝐦𝐞 achieved $4.2M, compared to a net loss of $25.4M in Q3 2023.
➡️ 𝐆𝐫𝐨𝐬𝐬 𝐦𝐚𝐫𝐠𝐢𝐧 stood at 56%, down from 61% YoY due to higher service revenue.
➡️ 𝐓𝐨𝐭𝐚𝐥 𝐨𝐩𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐞𝐱𝐩𝐞𝐧𝐬𝐞𝐬 were $56.9M, decreased from $69.0M due to non-recurring R&D costs in 2023.
➡️ Increased 𝐑&𝐃 𝐢𝐧𝐯𝐞𝐬𝐭𝐦𝐞𝐧𝐭 and 𝐬𝐭𝐨𝐜𝐤 𝐜𝐨𝐦𝐩𝐞𝐧𝐬𝐚𝐭𝐢𝐨𝐧 expenses of $7.6M, up from $5.1M YoY.
➡️ 𝐂𝐚𝐬𝐡 𝐛𝐚𝐥𝐚𝐧𝐜𝐞 as of September 30, 2024, was $330.1M, down from $362.8M on June 30, 2024.
➡️ 𝐎𝐰𝐧𝐞𝐝 𝐭𝐨𝐭𝐚𝐥 𝐚𝐢𝐫𝐜𝐫𝐚𝐟𝐭 count reached 18 by quarter-end to support logistics.
➡️ Maintains 𝐠𝐮𝐢𝐝𝐚𝐧𝐜𝐞 for 2024 revenue of $425M to $445M, projecting 76%-84% YoY growth.
👉 CEO Statement:
“We are proud of our performance year to date and look forward to ending 2024 on a strong note,” said Waleed Hassanein, MD, President and Chief Executive Officer. “We continued to make meaningful progress across each of our growth initiatives through the third quarter and maintain our conviction in our growth runway for 2025 and beyond. Overall, we remain well on track to reach our stated target of achieving 10,000 OCS transplant cases per year in the U.S. by 2028.”

Last Seen Hashtags on Sotwe
Most Popular Users

Elon Musk 
@elonmusk
240.5M followers

Barack Obama 
@barackobama
118.7M followers

Cristiano Ronaldo 
@cristiano
114.4M followers

Donald J. Trump 
@realdonaldtrump
111.8M followers

Narendra Modi 
@narendramodi
107M followers

Rihanna 
@rihanna
98.7M followers

NASA 
@nasa
92.2M followers

Justin Bieber 
@justinbieber
91.8M followers

KATY PERRY 
@katyperry
90M followers

Taylor Swift 
@taylorswift13
83.9M followers

Lady Gaga 
@ladygaga
75.5M followers

Virat Kohli 
@imvkohli
73.4M followers

Kim Kardashian 
@kimkardashian
70.8M followers

YouTube 
@youtube
68.7M followers

Neymar Jr 
@neymarjr
66.3M followers

Bill Gates 
@billgates
65.2M followers

Selena Gomez 
@selenagomez
63M followers

The Ellen Show
@theellenshow
62.1M followers

CNN 
@cnn
61.7M followers

X 
@x
60.6M followers


















